fbpx

Take time to see if you qualify for any of the Oncology Clinical Trials provided by Quincy Medical group.

Study Description: QMGR # 91-105

Metastatic, Castration Resistant Prostate Cancer

Study Information: The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5′-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants with mCRPC who have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy.

Click Here to Read More

Contact Us:

E-mail the Study Coordinator for more information.


Study Description: QMGR # 91-104

Urothelial Carcinoma

Study Information: The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC).

Click Here to Read More

Contact Us:

E-mail the Study Coordinator for more information.



Study Description: QMG# 91-071

Connect MDS/AML Registry

This study is observational. An observational disease registry study means that only information about your disease and medical treatment that your study doctor is already prescribing as part of your standard medical care is collected. Standard medical care is the treatment normally given for a certain condition or illness. You will continue with your standard medical care and continue with any medicines you are now taking, office visits and laboratory testing according to the normal routine practices of your treating or study doctor(s). No additional medication, or payment for medication, is provided as part of this study. There is no investigational drug involved in this study. There will be no additional study visits, procedures, or testing required for this study. We will only collect this information as it relates to the standard medical care you are receiving.

Contact Us:

E-mail the Study Coordinator for more information.


Study Description: QMG# 91-079

Castration Resistant Prostate Cancer Registry

Study Information: The main reason why this registry is being set up is to describe patterns of care, disease assessment methods, treatment decisions, treatment settings,  physician referral patterns and to find out how your CRPC symptoms have improved while on your CRPC therapy.

Contact Us:

E-mail the Study Coordinator for more information.


Study Description: QMG# 91-086

Role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (BWEL Study)

Click Here to read more.

Contact Us:

E-mail the Study Coordinator for more information.


 

Study Description: QMG# 91-090

Palbociclib Registry for Advanced Breast Cancer (HR+ / HER2-)

Contact Us:

E-mail the Study Coordinator for more information.


Study Description: QMG# 91-092

Anemia due to Docetaxel in Solid tumors (mNSCLC, mBR or HRPC)

Click Here to read more.

Contact Us:

E-mail the Study Coordinator for more information.